Thread by @Lymenews

Next speaker
Albert Garcia-Romeu, PhD
Assistant Professor of Psychiatry and Behavioral Sciences @JHPsychedelics Johns Hopkins University School of Medicine
#LymeDiseaseAwarenessMonth

Albert Garcia-Romeu, PhD
Is working with psychedelics @JHPsychedelics
#LymeDiseaseAwarenessMonth

Albert Garcia-Romeu, PhD
The war on drugs has made it difficult to study these compounds. Although more recently there is more human research.
#LymeDiseaseAwarenessMonth

Albert Garcia-Romeu, PhD
Earlier studies have shown improvements in certain conditions. They are just beginning to look at Lyme disease
#LymeDiseaseAwarenessMonth

Albert Garcia-Romeu, PhD
The majority of patients upon follow-up report persisting positive effects from the psilocybin trials.
#LymeDiseaseAwarenessMonth

Albert Garcia-Romeu, PhD
Up to one year later patients are reporting benefits especially in their perception of well-being.
Warning: about 50% of patients have adverse events when the dose is too high.
#LymeDiseaseAwarenessMonth

Albert Garcia-Romeu, PhD
The patients who got the most out of the dosing sessions @JHPsychedelics had a support group.

Albert Garcia-Romeu, PhD
How does psilocybin work? Appears to be changes in serotonin receptors.

Albert Garcia-Romeu, PhD
These drugs also have anti-inflammatory properties and may be helpful in patients with post-treatment Lyme disease. Currently recruiting 20 patients for the first trial. #LymeDiseaseAwarenessMonth

Albert Garcia-Romeu, PhD
This is the time line of the #LymeDisease study and how they will be measuring outcomes.